Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDOCi
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
MDOCi, also referred to as micro dispersed derivatives of oxidised cellulose (MDOC), is a substance investigated for its potential anti-inflammatory and hypolipidemic effects. In an apolipoprotein-E-deficient (apoE(-/-)) mouse model of atherosclerosis, MDOCi was observed to significantly diminish the endothelial expression of vascular cell adhesion molecule (VCAM-1), a key participant in leukocyte adhesion and atherogenesis. While it showed an insignificant lowering of total cholesterol levels, its anti-inflammatory action on VCAM-1 suggests a potential benefit in atherosclerosis.
- Other names
- MDOCmicro dispersed derivatives of oxidised cellulose
02
Targets
VCAM1 (Vascular cell adhesion molecule 1)
Beyond the preview
Go deeper on MDOCi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDOCi.